Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Контрацепция после родов
Контрацепция после родов
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Абакарова П.Р. Внутриматочная гормональная система: особенности влияния на организм женщин (обзор литературы). Consilium Medicum 2003; 5: 203-9.
2. Абусуева З.А., Хашаева Т.Х.-М., Асланбекова А.А. Состояние лактационной функции в зависимости от экстренности проведения кесарева сечения. Рос. вестн. акуш.-гинекол. 2001; 1: 24–6.
3. Азанова Д.Б., Габидуллина Р.И., Резвяков П.Н. Морфологическое исследование биоптатов миометрия после кесарева сечения. 4-й Рос. науч. форум "Охрана здоровья матери и ребенка ". Тез. докл. М., 2002; 8–9.
4. Арзамасцев А.П., Садчикова Н.О. Контрацептивные средства: прогресс продолжается. Consilium Medicum 2001; 5: 160–5.
5. Бабюк И.А., Мирович Д.Ю. Современная контрацепция: контрацепция в послеродовом периоде, неотложная контрацепция для подростков. М.: АСТ, 2004.
6. Багдань Ш. (ред.) Современное предупреждение беременности и планирование семьи. Будапешт: Графит Пенсил, 1998.
7. Вихляева Е.М., Николаева Е.И. Возможность выбора и приемлемость различных методов контрацепции после родов. Акуш. и гинекол. 2003; 6: 20–4.
8. Вялков А.И., Чеченин Г.И., Сырцова Л.Е. Потребности и возможности общественного здоровья. Бюлл. нац. НИИ обществ. здоровья. 2005; 4: 41–5.
9. Зарубина Е.И., Прилепская В.Н., Смирнова А.А. Проблемы послеродовой контрацепции. Кремлевская медицина. Клин. вестн. 1999; 2: 12–5.
10. Краснопольский В.И., Серова О.Ф., Туманова В.А., Зароченцева В.А. Патогенетическое обоснование лечения дисменореи. Вопр. гинекол., акуш. и перинатол. 2005; 4 (1): 72–7.
11. Кулаков В.И. Новые технологии и научные приоритеты в акушерстве и гинекологии. Consilium Medicum 2007; 1: 5-7.
12. Курбанова М.Х. Приемлемость и эффективность средств контрацепции при некоторых формах экстрагенитальной и акушерской патологии. Автореф. дис. ... докт. мед. наук. Душанбе, 1997.
13. Матвеева Е.Г. Оптимизация методов контрацепции у женщин после кесарева сечения. Автореф. дис. ... канд. мед. наук. Казань, 2000.
14. Межевитинова Е.А. Барьерные методы контрацепции как профилактика развития инфекций, передающихся половым путем, и патологии шейки матки. Consilium Medicum 2001; 4: 147–9.
15. Межевитинова Е.А. Клинико-фармакологические аспекты гестагенной контрацепции. Контрацепция и здоровье женщины. 1998; 2: 29–39.
16. Николаева Е.И., Тохиян А.А. Оценка современных перинатальных технологий у беременных и рожениц высокого риска. Вестн. акуш.-гинекол. 1998; 1: 26–8.
17. Прилепская В.Н., Яглов В.В. Гормональная контрацепция после родов. Обзор. Акуш. и гинекол. 1998; 1: 52–6.
18. Прилепская В.Н., Межевитинова Е.А., Назарова Н.М. и др. Контрацептивные и лечебные аспекты современных методов контрацепции: (клинич. лекции). М: МЕДпресс-информ, 2006.
19. Прилепская В.Н., Острейкова Л.И. Гормональная внутриматочная левоноргестрел-рилизинг-система "Мирена". Consilium Medicum 2005; 4: 38–40.
20. Прилепская В.Н., Ревазова Ф.С.. Внутриматочная контрацепция. Рос. вестн. акуш.-гинекол. 2001; 2: 60–4.
21. Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М., 2006.
22. Серова О.Ф. Особенности послеродовой контрацепции. Consilium Medicum 2005; 5/6: 292–3.
23. Тагиева А.В., Абакарова П.Р. Гормональная внутриматочная рилизинг-система "Мирена". Consilium Medicum 2005; 4: 29–30.
24. Фролова О.Г., Волгина В.Ф., Пугачева Т.Н. Контрацепция в послеродовом периоде. Планирование семьи. 1995; 3: 33–5.
25. Фролова О.Г., Токова З.З. Основные показатели деятельности акушерско-гинекологической службы и репродуктивного здоровья. Акуш. и гинекол. 2005; 1: 3–6.
26. Хэтчер Р.А., Ковал Д., Гест Ф. и др. Руководство по контрацепции: Рус. междунар. изд. Decatur: Bridging the Gap Commun. Inc., 1994.
27. Чернуха Е.А. Нормальный и патологический послеродовой период. [руководство]. М.: Гэотар-Медиа, 2006.
28. Четли Э. Проблемные лекарства. Рига, 1998.
29. Чивильгина В.В. Обоснование дифференцированных контрацептивных технологий у женщин в послеродовом периоде. Автореф. дис. ... канд. мед. наук. М., 2003.
30. Яглов В.В. Особенности репродуктивного поведения и контрацепции у женщин после родов. Автореф. дис. ... канд. мед. наук. М., 2000.
31. Abdollahi MC. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thrombosis, Haemostasis 2003; 89: 493–8.
32. Afifi M. Lactational amenorrhoea method for family planning and women empowerment in Egypt. Singapore Med J 2007; 48: 758–62.
33. Allen RE. Diaphragm fitting. Am Fam Physician 2004; 69: 97–100.
34. Barber SL. Family planning advice and postpartum contraceptive use among low-income women in Mexico. Int Fam Plan Perspect 2007; 33 (1): 6–12.
35. Blenning CE, Paladine H. An approach to the postpartum office visit. Amer Fam Physician 2005; 72 (12): 2491–6.
36. Bjarnadotti RI, Gottfredsdottir H, Sigurdardittir K et al. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women. Brit J Obstet Gynecol 2001; 108: 1174–80.
37. Bounds W. Female condoms. Eur J Contracept Reprod Health Care 1997; 2 (2): 113–6.
38. Buhimschi CS. Endocrinology of lactation. Obstet Gynecol Clin North Am 2004; 31 (4): 963–79.
39. Byrd JE, Hyde JS, DeLamater JD, Plant EA. Sexuality during pregnancy and the year postpartum. J Fam Pract 1998; 47: 305–8.
40. Campbell OM, Gray RH. Characteristics and determinants of postpartum ovarian function in women in the United States. Am J Obstet Gynecol 1993; 169 (1): 55–60.
41. Campbell SJ, Cropsey KL, Matthews CA. Intrauterine device use in a high-risk population: experience fr om an urban university clinic. Am J Obstet Gynecol 2007; 197 (2): 193.
42. Campino C, Torres C, Rioseco A et al. Plasma prolactin/oestradiol ratio at 38 weeks gestation predicts the duration of lactational amenorrhoea. Hum Reprod 2001; 16 (12): 2540–5.
43. Canto de Cetina T., Polanco-Reyes L. Lactational amenorrhoea as a method of family planning. Salud Publica Mex 1996; 38: 58–63.
44. Chatterton RT Jr, Hill PD, Aldag JC et al. Relation of plasma oxytocin and prolactin concentrations to milk production in mothers of preterm infants: influence of stress. J Clin Endocrinol Metab 2000; 85 (10): 3661–8.
45. De Stefano V, Rossi E, Leone G. Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications. Semin Vasc Med 2003; 3: 47–60.
46. Diaz J, Bahamondes I, Monteiro CA et al. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brasil. Contraception 2001; 62: 59–61.
47. El-Shafei M. Postpartum and postabortion intrauterine device insertion unmet needs of safe reproductive health: three year experience of Mansoura University Hospital. Eur J Contracep Reprod Health Care 2000; 26: 253–62.
48. Eroglu K, Akkuzu G, Vural G et al. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception 2006; 74 (5): 376–81.
49. Finger WR, Best K. The copper IUD. Network (electronic version), 2000; 20 (1).
50. Gilliam ML, Derman RJ. Barrier methods of contraception. Obstet Gynecol Clin North Am 2000; 27 (4): 841–58.
51. Giugliani ER. Common problems during lactation and their management. Pediatr (Rio J) 2004; 80 (Suppl. 5): S147–54.
52. Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of IUD trials: lessons learned. Contraception 2007; 75 (Suppl. 6): S55–9.
53. Guthmann RA, Bang J, Nashelsky J. Combined oral contraceptives for mothers who are breastfeeding. Am Fam Physician 2005; 72 (7): 1303-4.
54. Hamerlynck JV, Knuist M. Modern intra-uterine contraception: a better option. Ned Tijdschr Geneeskd 2001; 145: 1621–4.
55. Harrison-Woolrych M, Ashton J, Coulter D. Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported? Contraception 2003; 67: 53–6.
56. Hayes JL, Cwiak C, Goedken P, Zieman M. A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. Contraception 2007; 76: 292–6.
57. Hatcher RA, Zieman M, Cwiak C et al. A pocket guide to managing contraception. Tiger: Bridging the Gap Foundation, 2005.
58. Hildebrandt H.M. Maternal perception of lactogenesis time: a clinical report. J Hum Lact 1999; 15 (4): 317–23.
59. Hill PD, Aldag JC, Chatterton RT, Zinaman M. Psychological distress and milk volume in lactating mothers. West J Nurs Res 2005; 27 (6): 676–93.
60. Hill PD, Chatterton RTJr, Aldag JC. Serum prolactin in breastfeeding: state of the science. Biol Res Nurs 1999; 1 (1): 65–75.
61. Hiller JE, Griffith E, Jenner F. Education for contraceptive use by women after childbirth. Cochrane Database Syst Rev 2002; 3: CD001863.
62. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002; 57: 120–8.
63. Isley MM, Edelman A. Contraceptive implants: an overview and update. Obstet Gynecol Clin North Am 2007; 34: 73–90.
64. Jones RL, Critchley HO. Morphological and functional changes in the human endometrium following intra-uterine levonorgestrel delivery. Hum Reprod 2000; 15 (Suppl. 3): 162-72.
65. Johansen JR, Dupont M, Obel EB. Insertion of intrauterine device in general practice. Which women choose the IUD, and how is the procedure done? Ugeskr Laeger 2001; 163: 4574–7.
66. Johansson E, Oldin V. The passage of exogenous hormones into breast milk – Possible effects. Int J Gynaec Obstet 1987; 25: 111–4.
67. Kennedy KI, Short RV, Tully MR. Premature introduction of progestin-only contraceptive methods during lactation. Contraception 1997; 55 (6): 347–50.
68. Khella AK, Fahim HI, Issa AH et al. Lactational amenorrhea as a method of family planning in Egypt. Contraception 2004; 69: 317–22.
69. Kremer JA, Rolland R, van der Heijden PF et al. Return of gonadotropic function in postpartum women during bromocriptine treatment. Fertil Steril 1989; 51 (4): 622–7.
70. Latka M. Female-initiated barrier methods for the prevention of STI/HIV: where are we now? Wh ere should we go? J Urban Health 2001; 78 (4): 571–80.
71. Lesnewski R, Prine L. Initiating hormonal contraception. Am Fam Physician 2006; 74: 105-12.
72. Lewis PR, Brown JB, Renfree MB, Short RV. The resumption of ovulation and menstruation in a well-nourished population of women breastfeeding for an extended period of time. Fertil Steril 1991; 55: 529–36.
73. Li W, Qiu Y. Relation of supplementary feeding to resumptions of menstruation and ovulation in lactating postpartum women. Chin Med J (Engl) 2007; 120 (10): 868–70.
74. Lombrain P, Cathelineau G. Hypertension, heart disease. Contracept Fertil Sexual 1985; 1, (Suppl.): 127–31.
75. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2007; 2: CD006133.
76. Lovelady CA. Is maternal obesity a cause of poor lactation performance. Nutr Rev 2005; 63 (10): 352–5.
77. Mauck C, Callahan M, Weiner DH, Dominik R. A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex diaphragm. The FemCap Investigators' Group. Contraception 1999; 60 (2): 71–80.
78. McNeilly AS. Neuroendocrine changes and fertility in breast-feeding women. Prog Brain Res 2001; 133: 207–14.
79. Meirik O. Intrauterine devices – upper and lower genital tract infections. Contraception 2007; 75 (Suppl. 6): S41–7.
80. Nelson AL. Reversible female contraception: current options and new developments. Expert Rev Med Devices 2007; 4 (2): 241–52.
81. Olatinwo AW, Anate M, Balogun OR, Alao MO. Intrauterine contraceptive device (IUCD): socio-demographic characteristics of acceptors, acceptability and effectiveness in a teaching hospital in Nigeria. Niger J Med 2001; 10: 14–7.
82. Olayemi O, Omigbodun AA, Obajimi MO et al. Ultrasound assessment of the effect of parity on postpartum uterine involution. J Obstet Gynaecol 2002; 22: 381–4.
83. Piejko E. The postpartum visit. Why wait for 6 weeks? Austr Fam Physician 2006; 35 (9): 674–8.
84. Puzey M. MirenaR at caesarean section. Eur J Contracept Reprod Health Care 2005; 10 (3): 164–7.
85. Qiu Y, Xu ZH, Wang LG. Study on the first menses and ovulation in 791 lactating postpartum women. Chin J Fam Plann (Chin) 2001; 9: 346–8.
86. Rowland M, Foxcroft L, Hopman WM, Patel R. Breastfeeding and sexuality immediately post partum. Can Fam Physic 2005; 51: 1366–7.
87. Sahmay S, Kaleli S, Oral E, Alper T. Effect of different types of intrauterine devices on intrauterine activity. Int J Fertil Womens Med 1999; 44: 150–5.
88. Salem RM. New attention to the IUD: expanding women's contraceptive options to meet their needs. Popul Rep B 2006; 7: 1–26.
89. Scott JA, Binns CW, Oddy WH. Predictors of delayed onset of lactation. Matern Child Nutr 2007; 3 (3): 186–93.
90. Shaamash AH, Sayed GH, Hussien MM, Shaaban MM. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception 2005; 72 (5): 346–51.
91. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception 2007; 75 (Suppl. 6): S70–5.
92. Smith GC, Pell JP, Dobbie R. Interpregnancy interval and risk of preterm birth and neonatal death: retrospective cohort study. BMJ 2003; 327 (7410): 313.
93. Speroff L, Darney P. A clinical guide for contraception. 2nd ed. Baltimore: Williams & Wilkins, 1996.
94. Stanwood NL, Garrett JM, Konrad TR. Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. Obstet Gynecol 2002; 99: 275–80.
95. Starczewski A. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Gynecol Pol 2000; 71: 1221–5.
96. Taneepanichskul S, Reinprayoon D, Thaithumyanon P et al. Effects of the etonogestrel-releasing implant Implanon and a nonmedicated intrauterine device on the growth of breast-fed infants. Contraception 2006; 73 (4): 368–71.
97. Tankeyoon M, Dusitsin N, Chalapati S et al. Effects of hormonal contraceptives on milk volume and infant growth. WHO Special Programme of Research, Development and Research Training in Human Reproduction Task force on oral contraceptives. Contraception 1984; 30 (6): 505–22.
98. Tennekoon KH. Maternal prolactin concentrations and lactational behaviour in the early postpartum period in women with lactational amenorrhoea. Ceylon Med J 2001; 46 (1): 6–10.
99. Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod 2006; 21 (10): 2612–6.
100. Truitt ST, Fraser AB, Grimes DA et al. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev 2003; 2: CD003988.
101. Vald_s GP, Orellana CJJ. Post suckling prolactin and estradiol levels as predictors of the time of appearance of the first post partum menstruation. Rev Med Chil 2007; 135 (4): 419–26.
102. Van der Wijden C, Kleijnen J, Van den Berk T. Lactational amenorrhea for family planning. Cochrane Database Syst Rev 2003; 4: CD001329.
103. Vikat A, Kosunen E, Rimpela M. Risk of postpartum induced abortion in Finland: A register-based study. Persp Reprod Sexual Health 2002; 34: 84–90.
104. Welcovic S, Costa L, Faundes A et al. Postpartum bleeding and infection and postplacental IUD insertion. Contraception 2001; 63: 155–8.
105. Williams LM, Morrow B, Lansky A et al. Surveillance for selected maternal behaviors and experiences before, during, and after pregnancy. Pregnancy Risk Assessment Monitoring System (PRAMS), 2000. MMWR Surveill Sum 2003; 52 (11): 1–14.
106. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization, 2004.
107. World Health Organization. Postpartum care of the mother and newborn: a practical guide. Geneva, 1998. http://www.who.int/reproductive-health/publications/ msm_98_3/.
108. Zhang HY, Qin AP, Han P. Study on uterine involution and endometrial and ovary alteration of postpartum lactating women by trans-vaginal ultrasound (TVS). J Guangxi Med Univ 2006; 23: 46–7.
109. Zhu BP. Effect of interpregnancy interval on birth outcomes: findings from three recent U.S. studies. Int J Gynaec Obstet 2005; 89 (Suppl. 1): S25–S33.
110. Zurawin RK, Ayensu-Coker L. Innovations in contraception: a review. Clin Obstet Gynecol 2007; 50 (2): 425–39.
2. Абусуева З.А., Хашаева Т.Х.-М., Асланбекова А.А. Состояние лактационной функции в зависимости от экстренности проведения кесарева сечения. Рос. вестн. акуш.-гинекол. 2001; 1: 24–6.
3. Азанова Д.Б., Габидуллина Р.И., Резвяков П.Н. Морфологическое исследование биоптатов миометрия после кесарева сечения. 4-й Рос. науч. форум "Охрана здоровья матери и ребенка ". Тез. докл. М., 2002; 8–9.
4. Арзамасцев А.П., Садчикова Н.О. Контрацептивные средства: прогресс продолжается. Consilium Medicum 2001; 5: 160–5.
5. Бабюк И.А., Мирович Д.Ю. Современная контрацепция: контрацепция в послеродовом периоде, неотложная контрацепция для подростков. М.: АСТ, 2004.
6. Багдань Ш. (ред.) Современное предупреждение беременности и планирование семьи. Будапешт: Графит Пенсил, 1998.
7. Вихляева Е.М., Николаева Е.И. Возможность выбора и приемлемость различных методов контрацепции после родов. Акуш. и гинекол. 2003; 6: 20–4.
8. Вялков А.И., Чеченин Г.И., Сырцова Л.Е. Потребности и возможности общественного здоровья. Бюлл. нац. НИИ обществ. здоровья. 2005; 4: 41–5.
9. Зарубина Е.И., Прилепская В.Н., Смирнова А.А. Проблемы послеродовой контрацепции. Кремлевская медицина. Клин. вестн. 1999; 2: 12–5.
10. Краснопольский В.И., Серова О.Ф., Туманова В.А., Зароченцева В.А. Патогенетическое обоснование лечения дисменореи. Вопр. гинекол., акуш. и перинатол. 2005; 4 (1): 72–7.
11. Кулаков В.И. Новые технологии и научные приоритеты в акушерстве и гинекологии. Consilium Medicum 2007; 1: 5-7.
12. Курбанова М.Х. Приемлемость и эффективность средств контрацепции при некоторых формах экстрагенитальной и акушерской патологии. Автореф. дис. ... докт. мед. наук. Душанбе, 1997.
13. Матвеева Е.Г. Оптимизация методов контрацепции у женщин после кесарева сечения. Автореф. дис. ... канд. мед. наук. Казань, 2000.
14. Межевитинова Е.А. Барьерные методы контрацепции как профилактика развития инфекций, передающихся половым путем, и патологии шейки матки. Consilium Medicum 2001; 4: 147–9.
15. Межевитинова Е.А. Клинико-фармакологические аспекты гестагенной контрацепции. Контрацепция и здоровье женщины. 1998; 2: 29–39.
16. Николаева Е.И., Тохиян А.А. Оценка современных перинатальных технологий у беременных и рожениц высокого риска. Вестн. акуш.-гинекол. 1998; 1: 26–8.
17. Прилепская В.Н., Яглов В.В. Гормональная контрацепция после родов. Обзор. Акуш. и гинекол. 1998; 1: 52–6.
18. Прилепская В.Н., Межевитинова Е.А., Назарова Н.М. и др. Контрацептивные и лечебные аспекты современных методов контрацепции: (клинич. лекции). М: МЕДпресс-информ, 2006.
19. Прилепская В.Н., Острейкова Л.И. Гормональная внутриматочная левоноргестрел-рилизинг-система "Мирена". Consilium Medicum 2005; 4: 38–40.
20. Прилепская В.Н., Ревазова Ф.С.. Внутриматочная контрацепция. Рос. вестн. акуш.-гинекол. 2001; 2: 60–4.
21. Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М., 2006.
22. Серова О.Ф. Особенности послеродовой контрацепции. Consilium Medicum 2005; 5/6: 292–3.
23. Тагиева А.В., Абакарова П.Р. Гормональная внутриматочная рилизинг-система "Мирена". Consilium Medicum 2005; 4: 29–30.
24. Фролова О.Г., Волгина В.Ф., Пугачева Т.Н. Контрацепция в послеродовом периоде. Планирование семьи. 1995; 3: 33–5.
25. Фролова О.Г., Токова З.З. Основные показатели деятельности акушерско-гинекологической службы и репродуктивного здоровья. Акуш. и гинекол. 2005; 1: 3–6.
26. Хэтчер Р.А., Ковал Д., Гест Ф. и др. Руководство по контрацепции: Рус. междунар. изд. Decatur: Bridging the Gap Commun. Inc., 1994.
27. Чернуха Е.А. Нормальный и патологический послеродовой период. [руководство]. М.: Гэотар-Медиа, 2006.
28. Четли Э. Проблемные лекарства. Рига, 1998.
29. Чивильгина В.В. Обоснование дифференцированных контрацептивных технологий у женщин в послеродовом периоде. Автореф. дис. ... канд. мед. наук. М., 2003.
30. Яглов В.В. Особенности репродуктивного поведения и контрацепции у женщин после родов. Автореф. дис. ... канд. мед. наук. М., 2000.
31. Abdollahi MC. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thrombosis, Haemostasis 2003; 89: 493–8.
32. Afifi M. Lactational amenorrhoea method for family planning and women empowerment in Egypt. Singapore Med J 2007; 48: 758–62.
33. Allen RE. Diaphragm fitting. Am Fam Physician 2004; 69: 97–100.
34. Barber SL. Family planning advice and postpartum contraceptive use among low-income women in Mexico. Int Fam Plan Perspect 2007; 33 (1): 6–12.
35. Blenning CE, Paladine H. An approach to the postpartum office visit. Amer Fam Physician 2005; 72 (12): 2491–6.
36. Bjarnadotti RI, Gottfredsdottir H, Sigurdardittir K et al. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women. Brit J Obstet Gynecol 2001; 108: 1174–80.
37. Bounds W. Female condoms. Eur J Contracept Reprod Health Care 1997; 2 (2): 113–6.
38. Buhimschi CS. Endocrinology of lactation. Obstet Gynecol Clin North Am 2004; 31 (4): 963–79.
39. Byrd JE, Hyde JS, DeLamater JD, Plant EA. Sexuality during pregnancy and the year postpartum. J Fam Pract 1998; 47: 305–8.
40. Campbell OM, Gray RH. Characteristics and determinants of postpartum ovarian function in women in the United States. Am J Obstet Gynecol 1993; 169 (1): 55–60.
41. Campbell SJ, Cropsey KL, Matthews CA. Intrauterine device use in a high-risk population: experience fr om an urban university clinic. Am J Obstet Gynecol 2007; 197 (2): 193.
42. Campino C, Torres C, Rioseco A et al. Plasma prolactin/oestradiol ratio at 38 weeks gestation predicts the duration of lactational amenorrhoea. Hum Reprod 2001; 16 (12): 2540–5.
43. Canto de Cetina T., Polanco-Reyes L. Lactational amenorrhoea as a method of family planning. Salud Publica Mex 1996; 38: 58–63.
44. Chatterton RT Jr, Hill PD, Aldag JC et al. Relation of plasma oxytocin and prolactin concentrations to milk production in mothers of preterm infants: influence of stress. J Clin Endocrinol Metab 2000; 85 (10): 3661–8.
45. De Stefano V, Rossi E, Leone G. Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications. Semin Vasc Med 2003; 3: 47–60.
46. Diaz J, Bahamondes I, Monteiro CA et al. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brasil. Contraception 2001; 62: 59–61.
47. El-Shafei M. Postpartum and postabortion intrauterine device insertion unmet needs of safe reproductive health: three year experience of Mansoura University Hospital. Eur J Contracep Reprod Health Care 2000; 26: 253–62.
48. Eroglu K, Akkuzu G, Vural G et al. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception 2006; 74 (5): 376–81.
49. Finger WR, Best K. The copper IUD. Network (electronic version), 2000; 20 (1).
50. Gilliam ML, Derman RJ. Barrier methods of contraception. Obstet Gynecol Clin North Am 2000; 27 (4): 841–58.
51. Giugliani ER. Common problems during lactation and their management. Pediatr (Rio J) 2004; 80 (Suppl. 5): S147–54.
52. Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of IUD trials: lessons learned. Contraception 2007; 75 (Suppl. 6): S55–9.
53. Guthmann RA, Bang J, Nashelsky J. Combined oral contraceptives for mothers who are breastfeeding. Am Fam Physician 2005; 72 (7): 1303-4.
54. Hamerlynck JV, Knuist M. Modern intra-uterine contraception: a better option. Ned Tijdschr Geneeskd 2001; 145: 1621–4.
55. Harrison-Woolrych M, Ashton J, Coulter D. Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported? Contraception 2003; 67: 53–6.
56. Hayes JL, Cwiak C, Goedken P, Zieman M. A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. Contraception 2007; 76: 292–6.
57. Hatcher RA, Zieman M, Cwiak C et al. A pocket guide to managing contraception. Tiger: Bridging the Gap Foundation, 2005.
58. Hildebrandt H.M. Maternal perception of lactogenesis time: a clinical report. J Hum Lact 1999; 15 (4): 317–23.
59. Hill PD, Aldag JC, Chatterton RT, Zinaman M. Psychological distress and milk volume in lactating mothers. West J Nurs Res 2005; 27 (6): 676–93.
60. Hill PD, Chatterton RTJr, Aldag JC. Serum prolactin in breastfeeding: state of the science. Biol Res Nurs 1999; 1 (1): 65–75.
61. Hiller JE, Griffith E, Jenner F. Education for contraceptive use by women after childbirth. Cochrane Database Syst Rev 2002; 3: CD001863.
62. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002; 57: 120–8.
63. Isley MM, Edelman A. Contraceptive implants: an overview and update. Obstet Gynecol Clin North Am 2007; 34: 73–90.
64. Jones RL, Critchley HO. Morphological and functional changes in the human endometrium following intra-uterine levonorgestrel delivery. Hum Reprod 2000; 15 (Suppl. 3): 162-72.
65. Johansen JR, Dupont M, Obel EB. Insertion of intrauterine device in general practice. Which women choose the IUD, and how is the procedure done? Ugeskr Laeger 2001; 163: 4574–7.
66. Johansson E, Oldin V. The passage of exogenous hormones into breast milk – Possible effects. Int J Gynaec Obstet 1987; 25: 111–4.
67. Kennedy KI, Short RV, Tully MR. Premature introduction of progestin-only contraceptive methods during lactation. Contraception 1997; 55 (6): 347–50.
68. Khella AK, Fahim HI, Issa AH et al. Lactational amenorrhea as a method of family planning in Egypt. Contraception 2004; 69: 317–22.
69. Kremer JA, Rolland R, van der Heijden PF et al. Return of gonadotropic function in postpartum women during bromocriptine treatment. Fertil Steril 1989; 51 (4): 622–7.
70. Latka M. Female-initiated barrier methods for the prevention of STI/HIV: where are we now? Wh ere should we go? J Urban Health 2001; 78 (4): 571–80.
71. Lesnewski R, Prine L. Initiating hormonal contraception. Am Fam Physician 2006; 74: 105-12.
72. Lewis PR, Brown JB, Renfree MB, Short RV. The resumption of ovulation and menstruation in a well-nourished population of women breastfeeding for an extended period of time. Fertil Steril 1991; 55: 529–36.
73. Li W, Qiu Y. Relation of supplementary feeding to resumptions of menstruation and ovulation in lactating postpartum women. Chin Med J (Engl) 2007; 120 (10): 868–70.
74. Lombrain P, Cathelineau G. Hypertension, heart disease. Contracept Fertil Sexual 1985; 1, (Suppl.): 127–31.
75. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2007; 2: CD006133.
76. Lovelady CA. Is maternal obesity a cause of poor lactation performance. Nutr Rev 2005; 63 (10): 352–5.
77. Mauck C, Callahan M, Weiner DH, Dominik R. A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex diaphragm. The FemCap Investigators' Group. Contraception 1999; 60 (2): 71–80.
78. McNeilly AS. Neuroendocrine changes and fertility in breast-feeding women. Prog Brain Res 2001; 133: 207–14.
79. Meirik O. Intrauterine devices – upper and lower genital tract infections. Contraception 2007; 75 (Suppl. 6): S41–7.
80. Nelson AL. Reversible female contraception: current options and new developments. Expert Rev Med Devices 2007; 4 (2): 241–52.
81. Olatinwo AW, Anate M, Balogun OR, Alao MO. Intrauterine contraceptive device (IUCD): socio-demographic characteristics of acceptors, acceptability and effectiveness in a teaching hospital in Nigeria. Niger J Med 2001; 10: 14–7.
82. Olayemi O, Omigbodun AA, Obajimi MO et al. Ultrasound assessment of the effect of parity on postpartum uterine involution. J Obstet Gynaecol 2002; 22: 381–4.
83. Piejko E. The postpartum visit. Why wait for 6 weeks? Austr Fam Physician 2006; 35 (9): 674–8.
84. Puzey M. MirenaR at caesarean section. Eur J Contracept Reprod Health Care 2005; 10 (3): 164–7.
85. Qiu Y, Xu ZH, Wang LG. Study on the first menses and ovulation in 791 lactating postpartum women. Chin J Fam Plann (Chin) 2001; 9: 346–8.
86. Rowland M, Foxcroft L, Hopman WM, Patel R. Breastfeeding and sexuality immediately post partum. Can Fam Physic 2005; 51: 1366–7.
87. Sahmay S, Kaleli S, Oral E, Alper T. Effect of different types of intrauterine devices on intrauterine activity. Int J Fertil Womens Med 1999; 44: 150–5.
88. Salem RM. New attention to the IUD: expanding women's contraceptive options to meet their needs. Popul Rep B 2006; 7: 1–26.
89. Scott JA, Binns CW, Oddy WH. Predictors of delayed onset of lactation. Matern Child Nutr 2007; 3 (3): 186–93.
90. Shaamash AH, Sayed GH, Hussien MM, Shaaban MM. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception 2005; 72 (5): 346–51.
91. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception 2007; 75 (Suppl. 6): S70–5.
92. Smith GC, Pell JP, Dobbie R. Interpregnancy interval and risk of preterm birth and neonatal death: retrospective cohort study. BMJ 2003; 327 (7410): 313.
93. Speroff L, Darney P. A clinical guide for contraception. 2nd ed. Baltimore: Williams & Wilkins, 1996.
94. Stanwood NL, Garrett JM, Konrad TR. Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. Obstet Gynecol 2002; 99: 275–80.
95. Starczewski A. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Gynecol Pol 2000; 71: 1221–5.
96. Taneepanichskul S, Reinprayoon D, Thaithumyanon P et al. Effects of the etonogestrel-releasing implant Implanon and a nonmedicated intrauterine device on the growth of breast-fed infants. Contraception 2006; 73 (4): 368–71.
97. Tankeyoon M, Dusitsin N, Chalapati S et al. Effects of hormonal contraceptives on milk volume and infant growth. WHO Special Programme of Research, Development and Research Training in Human Reproduction Task force on oral contraceptives. Contraception 1984; 30 (6): 505–22.
98. Tennekoon KH. Maternal prolactin concentrations and lactational behaviour in the early postpartum period in women with lactational amenorrhoea. Ceylon Med J 2001; 46 (1): 6–10.
99. Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod 2006; 21 (10): 2612–6.
100. Truitt ST, Fraser AB, Grimes DA et al. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev 2003; 2: CD003988.
101. Vald_s GP, Orellana CJJ. Post suckling prolactin and estradiol levels as predictors of the time of appearance of the first post partum menstruation. Rev Med Chil 2007; 135 (4): 419–26.
102. Van der Wijden C, Kleijnen J, Van den Berk T. Lactational amenorrhea for family planning. Cochrane Database Syst Rev 2003; 4: CD001329.
103. Vikat A, Kosunen E, Rimpela M. Risk of postpartum induced abortion in Finland: A register-based study. Persp Reprod Sexual Health 2002; 34: 84–90.
104. Welcovic S, Costa L, Faundes A et al. Postpartum bleeding and infection and postplacental IUD insertion. Contraception 2001; 63: 155–8.
105. Williams LM, Morrow B, Lansky A et al. Surveillance for selected maternal behaviors and experiences before, during, and after pregnancy. Pregnancy Risk Assessment Monitoring System (PRAMS), 2000. MMWR Surveill Sum 2003; 52 (11): 1–14.
106. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization, 2004.
107. World Health Organization. Postpartum care of the mother and newborn: a practical guide. Geneva, 1998. http://www.who.int/reproductive-health/publications/ msm_98_3/.
108. Zhang HY, Qin AP, Han P. Study on uterine involution and endometrial and ovary alteration of postpartum lactating women by trans-vaginal ultrasound (TVS). J Guangxi Med Univ 2006; 23: 46–7.
109. Zhu BP. Effect of interpregnancy interval on birth outcomes: findings from three recent U.S. studies. Int J Gynaec Obstet 2005; 89 (Suppl. 1): S25–S33.
110. Zurawin RK, Ayensu-Coker L. Innovations in contraception: a review. Clin Obstet Gynecol 2007; 50 (2): 425–39.
2. Абусуева З.А., Хашаева Т.Х.-М., Асланбекова А.А. Состояние лактационной функции в зависимости от экстренности проведения кесарева сечения. Рос. вестн. акуш.-гинекол. 2001; 1: 24–6.
3. Азанова Д.Б., Габидуллина Р.И., Резвяков П.Н. Морфологическое исследование биоптатов миометрия после кесарева сечения. 4-й Рос. науч. форум "Охрана здоровья матери и ребенка ". Тез. докл. М., 2002; 8–9.
4. Арзамасцев А.П., Садчикова Н.О. Контрацептивные средства: прогресс продолжается. Consilium Medicum 2001; 5: 160–5.
5. Бабюк И.А., Мирович Д.Ю. Современная контрацепция: контрацепция в послеродовом периоде, неотложная контрацепция для подростков. М.: АСТ, 2004.
6. Багдань Ш. (ред.) Современное предупреждение беременности и планирование семьи. Будапешт: Графит Пенсил, 1998.
7. Вихляева Е.М., Николаева Е.И. Возможность выбора и приемлемость различных методов контрацепции после родов. Акуш. и гинекол. 2003; 6: 20–4.
8. Вялков А.И., Чеченин Г.И., Сырцова Л.Е. Потребности и возможности общественного здоровья. Бюлл. нац. НИИ обществ. здоровья. 2005; 4: 41–5.
9. Зарубина Е.И., Прилепская В.Н., Смирнова А.А. Проблемы послеродовой контрацепции. Кремлевская медицина. Клин. вестн. 1999; 2: 12–5.
10. Краснопольский В.И., Серова О.Ф., Туманова В.А., Зароченцева В.А. Патогенетическое обоснование лечения дисменореи. Вопр. гинекол., акуш. и перинатол. 2005; 4 (1): 72–7.
11. Кулаков В.И. Новые технологии и научные приоритеты в акушерстве и гинекологии. Consilium Medicum 2007; 1: 5-7.
12. Курбанова М.Х. Приемлемость и эффективность средств контрацепции при некоторых формах экстрагенитальной и акушерской патологии. Автореф. дис. ... докт. мед. наук. Душанбе, 1997.
13. Матвеева Е.Г. Оптимизация методов контрацепции у женщин после кесарева сечения. Автореф. дис. ... канд. мед. наук. Казань, 2000.
14. Межевитинова Е.А. Барьерные методы контрацепции как профилактика развития инфекций, передающихся половым путем, и патологии шейки матки. Consilium Medicum 2001; 4: 147–9.
15. Межевитинова Е.А. Клинико-фармакологические аспекты гестагенной контрацепции. Контрацепция и здоровье женщины. 1998; 2: 29–39.
16. Николаева Е.И., Тохиян А.А. Оценка современных перинатальных технологий у беременных и рожениц высокого риска. Вестн. акуш.-гинекол. 1998; 1: 26–8.
17. Прилепская В.Н., Яглов В.В. Гормональная контрацепция после родов. Обзор. Акуш. и гинекол. 1998; 1: 52–6.
18. Прилепская В.Н., Межевитинова Е.А., Назарова Н.М. и др. Контрацептивные и лечебные аспекты современных методов контрацепции: (клинич. лекции). М: МЕДпресс-информ, 2006.
19. Прилепская В.Н., Острейкова Л.И. Гормональная внутриматочная левоноргестрел-рилизинг-система "Мирена". Consilium Medicum 2005; 4: 38–40.
20. Прилепская В.Н., Ревазова Ф.С.. Внутриматочная контрацепция. Рос. вестн. акуш.-гинекол. 2001; 2: 60–4.
21. Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М., 2006.
22. Серова О.Ф. Особенности послеродовой контрацепции. Consilium Medicum 2005; 5/6: 292–3.
23. Тагиева А.В., Абакарова П.Р. Гормональная внутриматочная рилизинг-система "Мирена". Consilium Medicum 2005; 4: 29–30.
24. Фролова О.Г., Волгина В.Ф., Пугачева Т.Н. Контрацепция в послеродовом периоде. Планирование семьи. 1995; 3: 33–5.
25. Фролова О.Г., Токова З.З. Основные показатели деятельности акушерско-гинекологической службы и репродуктивного здоровья. Акуш. и гинекол. 2005; 1: 3–6.
26. Хэтчер Р.А., Ковал Д., Гест Ф. и др. Руководство по контрацепции: Рус. междунар. изд. Decatur: Bridging the Gap Commun. Inc., 1994.
27. Чернуха Е.А. Нормальный и патологический послеродовой период. [руководство]. М.: Гэотар-Медиа, 2006.
28. Четли Э. Проблемные лекарства. Рига, 1998.
29. Чивильгина В.В. Обоснование дифференцированных контрацептивных технологий у женщин в послеродовом периоде. Автореф. дис. ... канд. мед. наук. М., 2003.
30. Яглов В.В. Особенности репродуктивного поведения и контрацепции у женщин после родов. Автореф. дис. ... канд. мед. наук. М., 2000.
31. Abdollahi MC. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thrombosis, Haemostasis 2003; 89: 493–8.
32. Afifi M. Lactational amenorrhoea method for family planning and women empowerment in Egypt. Singapore Med J 2007; 48: 758–62.
33. Allen RE. Diaphragm fitting. Am Fam Physician 2004; 69: 97–100.
34. Barber SL. Family planning advice and postpartum contraceptive use among low-income women in Mexico. Int Fam Plan Perspect 2007; 33 (1): 6–12.
35. Blenning CE, Paladine H. An approach to the postpartum office visit. Amer Fam Physician 2005; 72 (12): 2491–6.
36. Bjarnadotti RI, Gottfredsdottir H, Sigurdardittir K et al. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women. Brit J Obstet Gynecol 2001; 108: 1174–80.
37. Bounds W. Female condoms. Eur J Contracept Reprod Health Care 1997; 2 (2): 113–6.
38. Buhimschi CS. Endocrinology of lactation. Obstet Gynecol Clin North Am 2004; 31 (4): 963–79.
39. Byrd JE, Hyde JS, DeLamater JD, Plant EA. Sexuality during pregnancy and the year postpartum. J Fam Pract 1998; 47: 305–8.
40. Campbell OM, Gray RH. Characteristics and determinants of postpartum ovarian function in women in the United States. Am J Obstet Gynecol 1993; 169 (1): 55–60.
41. Campbell SJ, Cropsey KL, Matthews CA. Intrauterine device use in a high-risk population: experience fr om an urban university clinic. Am J Obstet Gynecol 2007; 197 (2): 193.
42. Campino C, Torres C, Rioseco A et al. Plasma prolactin/oestradiol ratio at 38 weeks gestation predicts the duration of lactational amenorrhoea. Hum Reprod 2001; 16 (12): 2540–5.
43. Canto de Cetina T., Polanco-Reyes L. Lactational amenorrhoea as a method of family planning. Salud Publica Mex 1996; 38: 58–63.
44. Chatterton RT Jr, Hill PD, Aldag JC et al. Relation of plasma oxytocin and prolactin concentrations to milk production in mothers of preterm infants: influence of stress. J Clin Endocrinol Metab 2000; 85 (10): 3661–8.
45. De Stefano V, Rossi E, Leone G. Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications. Semin Vasc Med 2003; 3: 47–60.
46. Diaz J, Bahamondes I, Monteiro CA et al. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brasil. Contraception 2001; 62: 59–61.
47. El-Shafei M. Postpartum and postabortion intrauterine device insertion unmet needs of safe reproductive health: three year experience of Mansoura University Hospital. Eur J Contracep Reprod Health Care 2000; 26: 253–62.
48. Eroglu K, Akkuzu G, Vural G et al. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception 2006; 74 (5): 376–81.
49. Finger WR, Best K. The copper IUD. Network (electronic version), 2000; 20 (1).
50. Gilliam ML, Derman RJ. Barrier methods of contraception. Obstet Gynecol Clin North Am 2000; 27 (4): 841–58.
51. Giugliani ER. Common problems during lactation and their management. Pediatr (Rio J) 2004; 80 (Suppl. 5): S147–54.
52. Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of IUD trials: lessons learned. Contraception 2007; 75 (Suppl. 6): S55–9.
53. Guthmann RA, Bang J, Nashelsky J. Combined oral contraceptives for mothers who are breastfeeding. Am Fam Physician 2005; 72 (7): 1303-4.
54. Hamerlynck JV, Knuist M. Modern intra-uterine contraception: a better option. Ned Tijdschr Geneeskd 2001; 145: 1621–4.
55. Harrison-Woolrych M, Ashton J, Coulter D. Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported? Contraception 2003; 67: 53–6.
56. Hayes JL, Cwiak C, Goedken P, Zieman M. A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. Contraception 2007; 76: 292–6.
57. Hatcher RA, Zieman M, Cwiak C et al. A pocket guide to managing contraception. Tiger: Bridging the Gap Foundation, 2005.
58. Hildebrandt H.M. Maternal perception of lactogenesis time: a clinical report. J Hum Lact 1999; 15 (4): 317–23.
59. Hill PD, Aldag JC, Chatterton RT, Zinaman M. Psychological distress and milk volume in lactating mothers. West J Nurs Res 2005; 27 (6): 676–93.
60. Hill PD, Chatterton RTJr, Aldag JC. Serum prolactin in breastfeeding: state of the science. Biol Res Nurs 1999; 1 (1): 65–75.
61. Hiller JE, Griffith E, Jenner F. Education for contraceptive use by women after childbirth. Cochrane Database Syst Rev 2002; 3: CD001863.
62. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002; 57: 120–8.
63. Isley MM, Edelman A. Contraceptive implants: an overview and update. Obstet Gynecol Clin North Am 2007; 34: 73–90.
64. Jones RL, Critchley HO. Morphological and functional changes in the human endometrium following intra-uterine levonorgestrel delivery. Hum Reprod 2000; 15 (Suppl. 3): 162-72.
65. Johansen JR, Dupont M, Obel EB. Insertion of intrauterine device in general practice. Which women choose the IUD, and how is the procedure done? Ugeskr Laeger 2001; 163: 4574–7.
66. Johansson E, Oldin V. The passage of exogenous hormones into breast milk – Possible effects. Int J Gynaec Obstet 1987; 25: 111–4.
67. Kennedy KI, Short RV, Tully MR. Premature introduction of progestin-only contraceptive methods during lactation. Contraception 1997; 55 (6): 347–50.
68. Khella AK, Fahim HI, Issa AH et al. Lactational amenorrhea as a method of family planning in Egypt. Contraception 2004; 69: 317–22.
69. Kremer JA, Rolland R, van der Heijden PF et al. Return of gonadotropic function in postpartum women during bromocriptine treatment. Fertil Steril 1989; 51 (4): 622–7.
70. Latka M. Female-initiated barrier methods for the prevention of STI/HIV: where are we now? Wh ere should we go? J Urban Health 2001; 78 (4): 571–80.
71. Lesnewski R, Prine L. Initiating hormonal contraception. Am Fam Physician 2006; 74: 105-12.
72. Lewis PR, Brown JB, Renfree MB, Short RV. The resumption of ovulation and menstruation in a well-nourished population of women breastfeeding for an extended period of time. Fertil Steril 1991; 55: 529–36.
73. Li W, Qiu Y. Relation of supplementary feeding to resumptions of menstruation and ovulation in lactating postpartum women. Chin Med J (Engl) 2007; 120 (10): 868–70.
74. Lombrain P, Cathelineau G. Hypertension, heart disease. Contracept Fertil Sexual 1985; 1, (Suppl.): 127–31.
75. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2007; 2: CD006133.
76. Lovelady CA. Is maternal obesity a cause of poor lactation performance. Nutr Rev 2005; 63 (10): 352–5.
77. Mauck C, Callahan M, Weiner DH, Dominik R. A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex diaphragm. The FemCap Investigators' Group. Contraception 1999; 60 (2): 71–80.
78. McNeilly AS. Neuroendocrine changes and fertility in breast-feeding women. Prog Brain Res 2001; 133: 207–14.
79. Meirik O. Intrauterine devices – upper and lower genital tract infections. Contraception 2007; 75 (Suppl. 6): S41–7.
80. Nelson AL. Reversible female contraception: current options and new developments. Expert Rev Med Devices 2007; 4 (2): 241–52.
81. Olatinwo AW, Anate M, Balogun OR, Alao MO. Intrauterine contraceptive device (IUCD): socio-demographic characteristics of acceptors, acceptability and effectiveness in a teaching hospital in Nigeria. Niger J Med 2001; 10: 14–7.
82. Olayemi O, Omigbodun AA, Obajimi MO et al. Ultrasound assessment of the effect of parity on postpartum uterine involution. J Obstet Gynaecol 2002; 22: 381–4.
83. Piejko E. The postpartum visit. Why wait for 6 weeks? Austr Fam Physician 2006; 35 (9): 674–8.
84. Puzey M. MirenaR at caesarean section. Eur J Contracept Reprod Health Care 2005; 10 (3): 164–7.
85. Qiu Y, Xu ZH, Wang LG. Study on the first menses and ovulation in 791 lactating postpartum women. Chin J Fam Plann (Chin) 2001; 9: 346–8.
86. Rowland M, Foxcroft L, Hopman WM, Patel R. Breastfeeding and sexuality immediately post partum. Can Fam Physic 2005; 51: 1366–7.
87. Sahmay S, Kaleli S, Oral E, Alper T. Effect of different types of intrauterine devices on intrauterine activity. Int J Fertil Womens Med 1999; 44: 150–5.
88. Salem RM. New attention to the IUD: expanding women's contraceptive options to meet their needs. Popul Rep B 2006; 7: 1–26.
89. Scott JA, Binns CW, Oddy WH. Predictors of delayed onset of lactation. Matern Child Nutr 2007; 3 (3): 186–93.
90. Shaamash AH, Sayed GH, Hussien MM, Shaaban MM. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception 2005; 72 (5): 346–51.
91. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception 2007; 75 (Suppl. 6): S70–5.
92. Smith GC, Pell JP, Dobbie R. Interpregnancy interval and risk of preterm birth and neonatal death: retrospective cohort study. BMJ 2003; 327 (7410): 313.
93. Speroff L, Darney P. A clinical guide for contraception. 2nd ed. Baltimore: Williams & Wilkins, 1996.
94. Stanwood NL, Garrett JM, Konrad TR. Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. Obstet Gynecol 2002; 99: 275–80.
95. Starczewski A. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Gynecol Pol 2000; 71: 1221–5.
96. Taneepanichskul S, Reinprayoon D, Thaithumyanon P et al. Effects of the etonogestrel-releasing implant Implanon and a nonmedicated intrauterine device on the growth of breast-fed infants. Contraception 2006; 73 (4): 368–71.
97. Tankeyoon M, Dusitsin N, Chalapati S et al. Effects of hormonal contraceptives on milk volume and infant growth. WHO Special Programme of Research, Development and Research Training in Human Reproduction Task force on oral contraceptives. Contraception 1984; 30 (6): 505–22.
98. Tennekoon KH. Maternal prolactin concentrations and lactational behaviour in the early postpartum period in women with lactational amenorrhoea. Ceylon Med J 2001; 46 (1): 6–10.
99. Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod 2006; 21 (10): 2612–6.
100. Truitt ST, Fraser AB, Grimes DA et al. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev 2003; 2: CD003988.
101. Vald_s GP, Orellana CJJ. Post suckling prolactin and estradiol levels as predictors of the time of appearance of the first post partum menstruation. Rev Med Chil 2007; 135 (4): 419–26.
102. Van der Wijden C, Kleijnen J, Van den Berk T. Lactational amenorrhea for family planning. Cochrane Database Syst Rev 2003; 4: CD001329.
103. Vikat A, Kosunen E, Rimpela M. Risk of postpartum induced abortion in Finland: A register-based study. Persp Reprod Sexual Health 2002; 34: 84–90.
104. Welcovic S, Costa L, Faundes A et al. Postpartum bleeding and infection and postplacental IUD insertion. Contraception 2001; 63: 155–8.
105. Williams LM, Morrow B, Lansky A et al. Surveillance for selected maternal behaviors and experiences before, during, and after pregnancy. Pregnancy Risk Assessment Monitoring System (PRAMS), 2000. MMWR Surveill Sum 2003; 52 (11): 1–14.
106. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization, 2004.
107. World Health Organization. Postpartum care of the mother and newborn: a practical guide. Geneva, 1998. http://www.who.int/reproductive-health/publications/ msm_98_3/.
108. Zhang HY, Qin AP, Han P. Study on uterine involution and endometrial and ovary alteration of postpartum lactating women by trans-vaginal ultrasound (TVS). J Guangxi Med Univ 2006; 23: 46–7.
109. Zhu BP. Effect of interpregnancy interval on birth outcomes: findings from three recent U.S. studies. Int J Gynaec Obstet 2005; 89 (Suppl. 1): S25–S33.
110. Zurawin RK, Ayensu-Coker L. Innovations in contraception: a review. Clin Obstet Gynecol 2007; 50 (2): 425–39.
________________________________________________
2. Абусуева З.А., Хашаева Т.Х.-М., Асланбекова А.А. Состояние лактационной функции в зависимости от экстренности проведения кесарева сечения. Рос. вестн. акуш.-гинекол. 2001; 1: 24–6.
3. Азанова Д.Б., Габидуллина Р.И., Резвяков П.Н. Морфологическое исследование биоптатов миометрия после кесарева сечения. 4-й Рос. науч. форум "Охрана здоровья матери и ребенка ". Тез. докл. М., 2002; 8–9.
4. Арзамасцев А.П., Садчикова Н.О. Контрацептивные средства: прогресс продолжается. Consilium Medicum 2001; 5: 160–5.
5. Бабюк И.А., Мирович Д.Ю. Современная контрацепция: контрацепция в послеродовом периоде, неотложная контрацепция для подростков. М.: АСТ, 2004.
6. Багдань Ш. (ред.) Современное предупреждение беременности и планирование семьи. Будапешт: Графит Пенсил, 1998.
7. Вихляева Е.М., Николаева Е.И. Возможность выбора и приемлемость различных методов контрацепции после родов. Акуш. и гинекол. 2003; 6: 20–4.
8. Вялков А.И., Чеченин Г.И., Сырцова Л.Е. Потребности и возможности общественного здоровья. Бюлл. нац. НИИ обществ. здоровья. 2005; 4: 41–5.
9. Зарубина Е.И., Прилепская В.Н., Смирнова А.А. Проблемы послеродовой контрацепции. Кремлевская медицина. Клин. вестн. 1999; 2: 12–5.
10. Краснопольский В.И., Серова О.Ф., Туманова В.А., Зароченцева В.А. Патогенетическое обоснование лечения дисменореи. Вопр. гинекол., акуш. и перинатол. 2005; 4 (1): 72–7.
11. Кулаков В.И. Новые технологии и научные приоритеты в акушерстве и гинекологии. Consilium Medicum 2007; 1: 5-7.
12. Курбанова М.Х. Приемлемость и эффективность средств контрацепции при некоторых формах экстрагенитальной и акушерской патологии. Автореф. дис. ... докт. мед. наук. Душанбе, 1997.
13. Матвеева Е.Г. Оптимизация методов контрацепции у женщин после кесарева сечения. Автореф. дис. ... канд. мед. наук. Казань, 2000.
14. Межевитинова Е.А. Барьерные методы контрацепции как профилактика развития инфекций, передающихся половым путем, и патологии шейки матки. Consilium Medicum 2001; 4: 147–9.
15. Межевитинова Е.А. Клинико-фармакологические аспекты гестагенной контрацепции. Контрацепция и здоровье женщины. 1998; 2: 29–39.
16. Николаева Е.И., Тохиян А.А. Оценка современных перинатальных технологий у беременных и рожениц высокого риска. Вестн. акуш.-гинекол. 1998; 1: 26–8.
17. Прилепская В.Н., Яглов В.В. Гормональная контрацепция после родов. Обзор. Акуш. и гинекол. 1998; 1: 52–6.
18. Прилепская В.Н., Межевитинова Е.А., Назарова Н.М. и др. Контрацептивные и лечебные аспекты современных методов контрацепции: (клинич. лекции). М: МЕДпресс-информ, 2006.
19. Прилепская В.Н., Острейкова Л.И. Гормональная внутриматочная левоноргестрел-рилизинг-система "Мирена". Consilium Medicum 2005; 4: 38–40.
20. Прилепская В.Н., Ревазова Ф.С.. Внутриматочная контрацепция. Рос. вестн. акуш.-гинекол. 2001; 2: 60–4.
21. Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М., 2006.
22. Серова О.Ф. Особенности послеродовой контрацепции. Consilium Medicum 2005; 5/6: 292–3.
23. Тагиева А.В., Абакарова П.Р. Гормональная внутриматочная рилизинг-система "Мирена". Consilium Medicum 2005; 4: 29–30.
24. Фролова О.Г., Волгина В.Ф., Пугачева Т.Н. Контрацепция в послеродовом периоде. Планирование семьи. 1995; 3: 33–5.
25. Фролова О.Г., Токова З.З. Основные показатели деятельности акушерско-гинекологической службы и репродуктивного здоровья. Акуш. и гинекол. 2005; 1: 3–6.
26. Хэтчер Р.А., Ковал Д., Гест Ф. и др. Руководство по контрацепции: Рус. междунар. изд. Decatur: Bridging the Gap Commun. Inc., 1994.
27. Чернуха Е.А. Нормальный и патологический послеродовой период. [руководство]. М.: Гэотар-Медиа, 2006.
28. Четли Э. Проблемные лекарства. Рига, 1998.
29. Чивильгина В.В. Обоснование дифференцированных контрацептивных технологий у женщин в послеродовом периоде. Автореф. дис. ... канд. мед. наук. М., 2003.
30. Яглов В.В. Особенности репродуктивного поведения и контрацепции у женщин после родов. Автореф. дис. ... канд. мед. наук. М., 2000.
31. Abdollahi MC. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thrombosis, Haemostasis 2003; 89: 493–8.
32. Afifi M. Lactational amenorrhoea method for family planning and women empowerment in Egypt. Singapore Med J 2007; 48: 758–62.
33. Allen RE. Diaphragm fitting. Am Fam Physician 2004; 69: 97–100.
34. Barber SL. Family planning advice and postpartum contraceptive use among low-income women in Mexico. Int Fam Plan Perspect 2007; 33 (1): 6–12.
35. Blenning CE, Paladine H. An approach to the postpartum office visit. Amer Fam Physician 2005; 72 (12): 2491–6.
36. Bjarnadotti RI, Gottfredsdottir H, Sigurdardittir K et al. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women. Brit J Obstet Gynecol 2001; 108: 1174–80.
37. Bounds W. Female condoms. Eur J Contracept Reprod Health Care 1997; 2 (2): 113–6.
38. Buhimschi CS. Endocrinology of lactation. Obstet Gynecol Clin North Am 2004; 31 (4): 963–79.
39. Byrd JE, Hyde JS, DeLamater JD, Plant EA. Sexuality during pregnancy and the year postpartum. J Fam Pract 1998; 47: 305–8.
40. Campbell OM, Gray RH. Characteristics and determinants of postpartum ovarian function in women in the United States. Am J Obstet Gynecol 1993; 169 (1): 55–60.
41. Campbell SJ, Cropsey KL, Matthews CA. Intrauterine device use in a high-risk population: experience fr om an urban university clinic. Am J Obstet Gynecol 2007; 197 (2): 193.
42. Campino C, Torres C, Rioseco A et al. Plasma prolactin/oestradiol ratio at 38 weeks gestation predicts the duration of lactational amenorrhoea. Hum Reprod 2001; 16 (12): 2540–5.
43. Canto de Cetina T., Polanco-Reyes L. Lactational amenorrhoea as a method of family planning. Salud Publica Mex 1996; 38: 58–63.
44. Chatterton RT Jr, Hill PD, Aldag JC et al. Relation of plasma oxytocin and prolactin concentrations to milk production in mothers of preterm infants: influence of stress. J Clin Endocrinol Metab 2000; 85 (10): 3661–8.
45. De Stefano V, Rossi E, Leone G. Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications. Semin Vasc Med 2003; 3: 47–60.
46. Diaz J, Bahamondes I, Monteiro CA et al. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brasil. Contraception 2001; 62: 59–61.
47. El-Shafei M. Postpartum and postabortion intrauterine device insertion unmet needs of safe reproductive health: three year experience of Mansoura University Hospital. Eur J Contracep Reprod Health Care 2000; 26: 253–62.
48. Eroglu K, Akkuzu G, Vural G et al. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception 2006; 74 (5): 376–81.
49. Finger WR, Best K. The copper IUD. Network (electronic version), 2000; 20 (1).
50. Gilliam ML, Derman RJ. Barrier methods of contraception. Obstet Gynecol Clin North Am 2000; 27 (4): 841–58.
51. Giugliani ER. Common problems during lactation and their management. Pediatr (Rio J) 2004; 80 (Suppl. 5): S147–54.
52. Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of IUD trials: lessons learned. Contraception 2007; 75 (Suppl. 6): S55–9.
53. Guthmann RA, Bang J, Nashelsky J. Combined oral contraceptives for mothers who are breastfeeding. Am Fam Physician 2005; 72 (7): 1303-4.
54. Hamerlynck JV, Knuist M. Modern intra-uterine contraception: a better option. Ned Tijdschr Geneeskd 2001; 145: 1621–4.
55. Harrison-Woolrych M, Ashton J, Coulter D. Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported? Contraception 2003; 67: 53–6.
56. Hayes JL, Cwiak C, Goedken P, Zieman M. A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. Contraception 2007; 76: 292–6.
57. Hatcher RA, Zieman M, Cwiak C et al. A pocket guide to managing contraception. Tiger: Bridging the Gap Foundation, 2005.
58. Hildebrandt H.M. Maternal perception of lactogenesis time: a clinical report. J Hum Lact 1999; 15 (4): 317–23.
59. Hill PD, Aldag JC, Chatterton RT, Zinaman M. Psychological distress and milk volume in lactating mothers. West J Nurs Res 2005; 27 (6): 676–93.
60. Hill PD, Chatterton RTJr, Aldag JC. Serum prolactin in breastfeeding: state of the science. Biol Res Nurs 1999; 1 (1): 65–75.
61. Hiller JE, Griffith E, Jenner F. Education for contraceptive use by women after childbirth. Cochrane Database Syst Rev 2002; 3: CD001863.
62. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002; 57: 120–8.
63. Isley MM, Edelman A. Contraceptive implants: an overview and update. Obstet Gynecol Clin North Am 2007; 34: 73–90.
64. Jones RL, Critchley HO. Morphological and functional changes in the human endometrium following intra-uterine levonorgestrel delivery. Hum Reprod 2000; 15 (Suppl. 3): 162-72.
65. Johansen JR, Dupont M, Obel EB. Insertion of intrauterine device in general practice. Which women choose the IUD, and how is the procedure done? Ugeskr Laeger 2001; 163: 4574–7.
66. Johansson E, Oldin V. The passage of exogenous hormones into breast milk – Possible effects. Int J Gynaec Obstet 1987; 25: 111–4.
67. Kennedy KI, Short RV, Tully MR. Premature introduction of progestin-only contraceptive methods during lactation. Contraception 1997; 55 (6): 347–50.
68. Khella AK, Fahim HI, Issa AH et al. Lactational amenorrhea as a method of family planning in Egypt. Contraception 2004; 69: 317–22.
69. Kremer JA, Rolland R, van der Heijden PF et al. Return of gonadotropic function in postpartum women during bromocriptine treatment. Fertil Steril 1989; 51 (4): 622–7.
70. Latka M. Female-initiated barrier methods for the prevention of STI/HIV: where are we now? Wh ere should we go? J Urban Health 2001; 78 (4): 571–80.
71. Lesnewski R, Prine L. Initiating hormonal contraception. Am Fam Physician 2006; 74: 105-12.
72. Lewis PR, Brown JB, Renfree MB, Short RV. The resumption of ovulation and menstruation in a well-nourished population of women breastfeeding for an extended period of time. Fertil Steril 1991; 55: 529–36.
73. Li W, Qiu Y. Relation of supplementary feeding to resumptions of menstruation and ovulation in lactating postpartum women. Chin Med J (Engl) 2007; 120 (10): 868–70.
74. Lombrain P, Cathelineau G. Hypertension, heart disease. Contracept Fertil Sexual 1985; 1, (Suppl.): 127–31.
75. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2007; 2: CD006133.
76. Lovelady CA. Is maternal obesity a cause of poor lactation performance. Nutr Rev 2005; 63 (10): 352–5.
77. Mauck C, Callahan M, Weiner DH, Dominik R. A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex diaphragm. The FemCap Investigators' Group. Contraception 1999; 60 (2): 71–80.
78. McNeilly AS. Neuroendocrine changes and fertility in breast-feeding women. Prog Brain Res 2001; 133: 207–14.
79. Meirik O. Intrauterine devices – upper and lower genital tract infections. Contraception 2007; 75 (Suppl. 6): S41–7.
80. Nelson AL. Reversible female contraception: current options and new developments. Expert Rev Med Devices 2007; 4 (2): 241–52.
81. Olatinwo AW, Anate M, Balogun OR, Alao MO. Intrauterine contraceptive device (IUCD): socio-demographic characteristics of acceptors, acceptability and effectiveness in a teaching hospital in Nigeria. Niger J Med 2001; 10: 14–7.
82. Olayemi O, Omigbodun AA, Obajimi MO et al. Ultrasound assessment of the effect of parity on postpartum uterine involution. J Obstet Gynaecol 2002; 22: 381–4.
83. Piejko E. The postpartum visit. Why wait for 6 weeks? Austr Fam Physician 2006; 35 (9): 674–8.
84. Puzey M. MirenaR at caesarean section. Eur J Contracept Reprod Health Care 2005; 10 (3): 164–7.
85. Qiu Y, Xu ZH, Wang LG. Study on the first menses and ovulation in 791 lactating postpartum women. Chin J Fam Plann (Chin) 2001; 9: 346–8.
86. Rowland M, Foxcroft L, Hopman WM, Patel R. Breastfeeding and sexuality immediately post partum. Can Fam Physic 2005; 51: 1366–7.
87. Sahmay S, Kaleli S, Oral E, Alper T. Effect of different types of intrauterine devices on intrauterine activity. Int J Fertil Womens Med 1999; 44: 150–5.
88. Salem RM. New attention to the IUD: expanding women's contraceptive options to meet their needs. Popul Rep B 2006; 7: 1–26.
89. Scott JA, Binns CW, Oddy WH. Predictors of delayed onset of lactation. Matern Child Nutr 2007; 3 (3): 186–93.
90. Shaamash AH, Sayed GH, Hussien MM, Shaaban MM. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception 2005; 72 (5): 346–51.
91. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception 2007; 75 (Suppl. 6): S70–5.
92. Smith GC, Pell JP, Dobbie R. Interpregnancy interval and risk of preterm birth and neonatal death: retrospective cohort study. BMJ 2003; 327 (7410): 313.
93. Speroff L, Darney P. A clinical guide for contraception. 2nd ed. Baltimore: Williams & Wilkins, 1996.
94. Stanwood NL, Garrett JM, Konrad TR. Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. Obstet Gynecol 2002; 99: 275–80.
95. Starczewski A. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Gynecol Pol 2000; 71: 1221–5.
96. Taneepanichskul S, Reinprayoon D, Thaithumyanon P et al. Effects of the etonogestrel-releasing implant Implanon and a nonmedicated intrauterine device on the growth of breast-fed infants. Contraception 2006; 73 (4): 368–71.
97. Tankeyoon M, Dusitsin N, Chalapati S et al. Effects of hormonal contraceptives on milk volume and infant growth. WHO Special Programme of Research, Development and Research Training in Human Reproduction Task force on oral contraceptives. Contraception 1984; 30 (6): 505–22.
98. Tennekoon KH. Maternal prolactin concentrations and lactational behaviour in the early postpartum period in women with lactational amenorrhoea. Ceylon Med J 2001; 46 (1): 6–10.
99. Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod 2006; 21 (10): 2612–6.
100. Truitt ST, Fraser AB, Grimes DA et al. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev 2003; 2: CD003988.
101. Vald_s GP, Orellana CJJ. Post suckling prolactin and estradiol levels as predictors of the time of appearance of the first post partum menstruation. Rev Med Chil 2007; 135 (4): 419–26.
102. Van der Wijden C, Kleijnen J, Van den Berk T. Lactational amenorrhea for family planning. Cochrane Database Syst Rev 2003; 4: CD001329.
103. Vikat A, Kosunen E, Rimpela M. Risk of postpartum induced abortion in Finland: A register-based study. Persp Reprod Sexual Health 2002; 34: 84–90.
104. Welcovic S, Costa L, Faundes A et al. Postpartum bleeding and infection and postplacental IUD insertion. Contraception 2001; 63: 155–8.
105. Williams LM, Morrow B, Lansky A et al. Surveillance for selected maternal behaviors and experiences before, during, and after pregnancy. Pregnancy Risk Assessment Monitoring System (PRAMS), 2000. MMWR Surveill Sum 2003; 52 (11): 1–14.
106. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization, 2004.
107. World Health Organization. Postpartum care of the mother and newborn: a practical guide. Geneva, 1998. http://www.who.int/reproductive-health/publications/ msm_98_3/.
108. Zhang HY, Qin AP, Han P. Study on uterine involution and endometrial and ovary alteration of postpartum lactating women by trans-vaginal ultrasound (TVS). J Guangxi Med Univ 2006; 23: 46–7.
109. Zhu BP. Effect of interpregnancy interval on birth outcomes: findings from three recent U.S. studies. Int J Gynaec Obstet 2005; 89 (Suppl. 1): S25–S33.
110. Zurawin RK, Ayensu-Coker L. Innovations in contraception: a review. Clin Obstet Gynecol 2007; 50 (2): 425–39.
Авторы
И.В.Кузнецова, М.Ю.Твалчрелидзе, В.А.Ананьев, В.А.Коновалов
Кафедра акушерства и гинекологии №1 лечебного факультета
Московской медицинской академии им. И.М.Сеченова (зав. – проф. А.И.Ищенко)
Кафедра акушерства и гинекологии №1 лечебного факультета
Московской медицинской академии им. И.М.Сеченова (зав. – проф. А.И.Ищенко)
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.